Loading
The only test designed to tell a woman who has finished five years of hormone therapy whether another five years is worth the side effects.
Breast Cancer Index (Biotheranostics, acquired by Hologic in 2021) is a laboratory-developed test for hormone-receptor-positive early breast cancer. Its HOXB13:IL17BR component was shown to predict benefit from extending endocrine therapy to 10 years in the MA.17, Trans-aTTom and IDEAL trial cohorts, and the ASCO and NCCN guidelines list it as the test for that decision; a prespecified NSABP B-42 analysis was less clear-cut. It also gives a late-recurrence risk (years 5 to 10). Medicare covers it. The test does not address the initial chemotherapy decision, which is the province of Oncotype DX, MammaPrint, Prosigna and EndoPredict.
RT-PCR combining the HOXB13:IL17BR ratio (predicts benefit from extended endocrine therapy) with the Molecular Grade Index (prognosis for late recurrence).
1.Breast Cancer Index slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Breast Cancer Index" OR ABSTRACT:"Breast Cancer Index") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Breast Cancer Index, not a curated reading list.
Shares EndoPredict, Oncotype DX, RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer and the tag test.
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares HR-positive / HER2-negative breast cancer and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares HR-positive / HER2-negative breast cancer and the tag test.